Juul in the rough.
In case you’ve ever wondered who can actually pay for the open access publication of their research, the e-cig company Juul is bankrolling a “scientific” campaign to convince the FDA it’s worth keeping on the market, including $51K on the publishing alone of 11 open access studies (Juul-funded, of course) concluding Juul products aid in smoking cessation. Juul, pay-per-view journals, who doesn’t win? Budding nicotine addicts. | Kaplan, New York Times 2021
Es un excelente artĂculo que ha escrito aquĂ sobre Juul. Su artĂculo me proporcionĂł algunos conocimientos Ăşnicos y Ăştiles. Gracias por llamar nuestra atenciĂłn sobre esta publicaciĂłn. Juul
ReplyDelete